Tirzepatide and nausea: is the profile genuinely different or just differently reported?

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

I would rather be precise about what I do not know than vague about what I do.

Post #11 and I disagree about the size of the effect, not about the direction.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

That is a description of practice, not a recommendation of it.

Injection-site reactions were reported at a low but non-zero rate across the trials. The practical point is that a reaction at one site does not predict a reaction at the next, and rotating properly makes the question moot.

If this contradicts something upthread, the upthread version may well be the better one.

Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.

On balance I think that is right, and I would not bet much on it.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.